Skip Navigation


International Immunology Advance Access originally published online on October 5, 2004
International Immunology 2004 16(11):1583-1594; doi:10.1093/intimm/dxh162
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary data
Right arrow All Versions of this Article:
16/11/1583    most recent
dxh162v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ferrant, J. L.
Right arrow Articles by Taylor, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrant, J. L.
Right arrow Articles by Taylor, F. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2004 The Japanese Society for Immunology

The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge

Janine L. Ferrant1, Christopher D. Benjamin1, Anne H. Cutler1, Susan L. Kalled1, Yen-Ming Hsu1, Ellen A. Garber1, Donna M. Hess1, Renee I. Shapiro1, Norma S. Kenyon2, David M. Harlan3, Allan D. Kirk3, Linda C. Burkly1 and Frederick R. Taylor1

1 Biogen Idec, Inc., 14 Cambridge Center, Cambridge, MA, USA
2 Diabetes Research Institute, University of Miami School of Medicine, Miami, FL, USA
3 Transplantation and Autoimmunity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

Correspondence to: J. L. Ferrant; E-mail: janine.ferrant-orgettas{at}biogenidec.com

Blockade of the CD154–CD40 co-stimulatory pathway with anti-CD154 mAbs has shown impressive efficacy in models of autoimmunity and allotransplantation. Clinical benefit was also demonstrated in systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia patients with the humanized anti-CD154 mAb, 5C8 (hu5C8). However, thromboembolic complications that occurred during the course of the hu5C8 clinical trials have proven to be a major setback to the field and safe alternative therapeutics targeting the CD154–CD40 pathway are of great interest. Recently, effector mechanisms have been shown to play a part in anti-CD154 mAb-induced transplant acceptance in murine models, while this issue remains unresolved for humoral-mediated models. Herein, aglycosyl anti-CD154 mAbs with reduced binding to Fc{gamma}R and complement were used as a novel means to test the role of effector mechanisms in non-human primate and murine models not amenable to gene knockout technology. While aglycosyl hu5C8 mAb was relatively ineffective in rhesus renal and islet allotransplantation, it inhibited primary and secondary humoral responses to a protein immunogen in cynomolgus monkeys. Moreover, an aglycosyl, chimeric MR1 mAb (muMR1) prolonged survival and inhibited pathogenic auto-antibody production in a murine model of SLE. Thus, the mechanisms required for efficacy of anti-CD154 mAbs depend on the nature of the immune challenge.

Keywords: antibody, co-stimulation, FcR, lupus, transplantation

Transmitting editor: F. S. Rosen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
L. A. Koopman Van Aarsen, D. R. Leone, S. Ho, B. M. Dolinski, P. E. McCoon, D. J. LePage, R. Kelly, G. Heaney, P. Rayhorn, C. Reid, et al.
Antibody-Mediated Blockade of Integrin {alpha}v 6 Inhibits Tumor Progression In vivo by a Transforming Growth Factor- Regulated Mechanism
Cancer Res., January 15, 2008; 68(2): 561 - 570.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. R. Hinton, J. M. Xiong, M. G. Johlfs, M. T. Tang, S. Keller, and N. Tsurushita
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
J. Immunol., January 1, 2006; 176(1): 346 - 356.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.